Biotechnology News and Research

RSS

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Atox Bio, a clinical stage biotechnology company engaged in the development of novel immunemodulators for severe infections in critically ill patients, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AB103, its lead product, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI).

10 Sep 2012

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.

10 Sep 2012

Simple low-cost biosensor to detect contaminated drinking water

Diarrheal disease is the second leading cause of death in children under five years old - killing as many as 1.5 million children worldwide every year. These startling statistics from the World Health Organization (2009) point to the reason why a group of undergraduate students from Arizona State University is working to develop a low-cost biosensor - a simple device that would detect contaminated drinking water.

7 Sep 2012

Videogames can be used for educational and treatment purposes for young people with ASD

According to the Centers for Disease Control and Prevention (CDC), 1 in 88 children in the U.S. has autism spectrum disorder (ASD), a broad group of neurodevelopmental disorders.

7 Sep 2012

Interleukin-18 plays a key role in inflammation

The naturally occurring cytokine interleukin-18, or IL-18, plays a key role in inflammation and has been implicated in serious inflammatory diseases for which the prognosis is poor and there are currently limited treatment options.

7 Sep 2012

New findings establish connection between microRNAs and cellular metabolism

New findings establish a connection between microRNAs and cellular metabolism, suggesting that a drug designed to inhibit these tiny molecules -- once considered to be "junk" DNA -- would have a positive effect against obesity.

7 Sep 2012

Ingenuity Systems, ShanghaiBio sign collaboration agreement

ShanghaiBio Corporation and Ingenuity Systems have signed a collaboration agreement enabling ShanghaiBio Corporation to extend its current lab service offering to include Ingenuity solutions for downstream analysis and interpretation of genomics data. ShanghaiBio Corporation will complement their sequencing, genotyping and gene expression lab services by creating a bundled solution with Ingenuity's applications, which combine analytics and biomedical content to help get actionable insights from experiments.

6 Sep 2012

CSHL publishes genome-wide analysis of transcripts produced within human cells

Most people understand genes to be specific segments of DNA that determine traits or diseases that are inherited. Textbooks suggest that genes are copied into RNA molecules, which are then used as templates for making protein - the highly diverse set of molecules that act as building blocks and engines of our cells. The truth, it now appears, is not so simple.

6 Sep 2012

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

Baxter International Inc. today announced that the company has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company's efforts to extend its oncology portfolio with advanced biological research and development.

From Baxter International Inc. 6 Sep 2012

UEA, IFR to study protective effects of broccoli consumption against prostate cancer

The Prostate Cancer Foundation is providing $1M of funding to the Institute of Food Research and the University of East Anglia (UEA) to study the protective effects of broccoli consumption against prostate cancer.

6 Sep 2012

Nordion third quarter revenue increases 0.5% to $67.1 million

Nordion Inc., a leading provider of products and services to the global health science market, today reported results for the fiscal third quarter ended July 31, 2012. The Company generated $67.1 million in revenue for the third quarter, an increase of $0.3 million, or 0.5%, over revenue of $66.8 million for the same period in 2011.

6 Sep 2012

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today complete results from its Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients.

6 Sep 2012

BioReliance introduces Reconstructed Skin Micronucleus Assay to detect DNA damage

Sigma-Aldrich Corporation today announced that its recent acquisition, BioReliance, the biopharma and early development services business under SAFC, will introduce a new assay to detect DNA damage from products with dermal routes of exposure. The Reconstructed Skin Micronucleus (RSMN) Assay represents the first commercial offering of a Genetic Toxicology assay using three-dimensional tissue models.

5 Sep 2012

New infrared spectroscopy technique to analyze pharmacological agent-protein interactions

RUB-Researchers from the Chair for Biophysics have developed a new method for the detailed study of the interaction between pharmaceuticals and their target proteins.

5 Sep 2012

Phase 1b trial validates efficacy of Pulmatrix PUR118 to treat COPD

Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, today announced top line results from a clinical study showing that the novel inhaled therapeutic, PUR118, demonstrated anti-inflammatory efficacy and was well-tolerated in two Phase 1b studies in patients with chronic obstructive pulmonary disease (COPD).

5 Sep 2012

Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B

Baxter International Inc. today announced that the company has submitted a biologics license application to the United States Food and Drug Administration for approval of BAX 326, a recombinant factor IX (rFIX) protein being investigated for the treatment and prophylaxis of bleeding episodes for patients over 12 years of age with hemophilia B.

From Baxter International Inc. 5 Sep 2012

ImmusanT commences Nexvax2 clinical trials for celiac disease in New Zealand, Australia and the U.S.

ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease. Nexvax2 is designed to re-establish patients' tolerance to the toxic effects of gluten, a protein in wheat, barley and rye, and allow them to return to a normal diet.

5 Sep 2012

AlloCure commences AC607 Phase 2 clinical trial for acute kidney injury

AlloCure, Inc. today announced that it has initiated a phase 2 clinical trial of AC607, the company's mesenchymal stem cell therapy, as a potential treatment for acute kidney injury.

5 Sep 2012

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.

4 Sep 2012

New analyses from Esbriet RECAP study in IPF patients presented at ERS 2012

InterMune, Inc. announced that new analyses of data from the RECAP extension study of Esbriet (pirfenidone) were presented today at the 2012 Annual Congress of the European Respiratory Society (ERS) in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, Germany.

3 Sep 2012

Biotechnology News and Research

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Simple low-cost biosensor to detect contaminated drinking water

Videogames can be used for educational and treatment purposes for young people with ASD

Interleukin-18 plays a key role in inflammation

New findings establish connection between microRNAs and cellular metabolism

Ingenuity Systems, ShanghaiBio sign collaboration agreement

CSHL publishes genome-wide analysis of transcripts produced within human cells

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

UEA, IFR to study protective effects of broccoli consumption against prostate cancer

Nordion third quarter revenue increases 0.5% to $67.1 million

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

BioReliance introduces Reconstructed Skin Micronucleus Assay to detect DNA damage

New infrared spectroscopy technique to analyze pharmacological agent-protein interactions

Phase 1b trial validates efficacy of Pulmatrix PUR118 to treat COPD

Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B

ImmusanT commences Nexvax2 clinical trials for celiac disease in New Zealand, Australia and the U.S.

AlloCure commences AC607 Phase 2 clinical trial for acute kidney injury

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

New analyses from Esbriet RECAP study in IPF patients presented at ERS 2012

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News